Servier Gets First FDA Nod for Targeted Therapy in Rare Type of Blood Cancer
Servier drug Tibsovo is now approved for treating advanced cases of myelodysplastic syndrome that have an IDH1 mutation. It’s the first approval of a targeted therapy for this type of cancer.